【作者】 吴万垠； 杨小兵； 龙顺钦； 邓宏； 蔡姣芝； 杨昌卫； 河文峰； 潘宗奇； 周宇姝； 欧阳育树； 廖桂雅；

【机构】 广东省中医院肿瘤科；

【摘要】 目的:观察扶正抗癌方联合吉非替尼治疗晚期非小细胞肺癌优势人群与非优势人群的有效性和安全性。方法:共纳入晚期NSCLC患者70例,均经病理组织学或细胞学检查确诊,其中49例完全符合优势人群的标准,即东方人种、女性、腺癌和非吸烟者;21例不符合者作为非优势人群,均接受扶正抗癌方(250ml,qd)联合吉非替尼(250mg,qd)治疗。结果:49例优势人群患者中CR 0例,达到PR 16例(32.7%),SD 30例(61.2%),PD 3例(6.1%),ORR为32.7%,DCR为93.9%;中位疾病无进展生存时间(PFS)8.2个月,治疗后中位生存期9.9个月。21例非优势人群患者中CR 0例,达到PR 5例(23.8%),SD 9例(42.9%),PD 7例(33.3%),ORR为23.8%,DCR为66.7%;中位疾病无进展生存时间(PFS)4.6个月,治疗后中位生存期7.9个月。二者有统计学差异。一线治疗时,优势人群及非优势人群的客观缓解率一致,均为21.4%。毒副反应较轻,耐受性可,大部分为1~2级,经对症治疗后症状缓解,不影响治疗。结论:抗癌扶正方联合吉非替尼治疗晚期非小细胞肺癌优势人群的疗效优于非优势人群;对于非优势人群,抗癌扶正方对吉非替尼可能有一定的增敏作用,值得进一步研究。更多还原

【Abstract】 Objective:To investigate the eficacy and toxicity of FuZhengKangAi(FZKA)decoction combines with Gefitinib in privilege and non-privilege population with advanced non-small cell lung cancer.Methods:Seventy patients of NSCLC with histologically or cytologically confirmed diagnosis treated with FuZhengKangAi decoction(250ml/d) combined with Gefitinib 250 mg / d.Among them,49 patients with NSCLC met with the dominant crowd criteria:East-Asianese,female,adenocarcinoma and non-smoking.21 patients didn’t meet the criteria.Results:Among the 49 patients with dominant crowd,none achieved a PR,16 patients achieved PR(32.7%),30 patients achieved SD(61.2%) and only 3 patients PD(6.1%).The overall response rate and the disease control rate were 32.7%and 93.9%,respectively.The median time of tumor progression free survival(PFS) was 8.2 months and the median time of survival(MST)after treatment was 9.9 months.The other 21 patients with non-dominant crowd,none achieved a PR,5 patients achieved PR(23.8%),9 patients achieved SD(42.9%),7 patients achieved PD(33.3%).The overall response rate and the disease control rate were 23.8%and 66.7%,respectively.The median time of tumor progression free survival(PFS) was 4.6 months and the median time of survival(MST) after treatment was 7.9 months.There was statistic difference between each other.In the first line treatment,the overall response rates of dominant crowd and non-dominant crowd were similar(both were 21.4%),the overall response rates of Adverse reactions were mild and reversible,and most reactions were at grade 1 to n.The Symptoms improved after symptomatic treatment.Conclusions:Our study suggests that response rate of FuZhengKangAi decoction combines with Gefitinib in the treatment of dominant crowd with advanced non-small cell lung cancer was superior to that of non-dominant crowd.FuZhengKangAi decoction may have sensitizing effect on Gefitinib in treating advanced NSCLC and it is worthy of further study.更多还原